MedTrace Logo

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

NCT04853927 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-03-04

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for COVID-19 patients in the intensive care unit

Conditions

  • Covid19
  • SARS (Severe Acute Respiratory Syndrome)

Interventions

DRUG

Proxalutamide

Proxalutamide 300mg q.d suspension

DRUG

Placebo

Proxalutamide 300mg q.d placebo

Sponsors & Collaborators

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel Fonseca, MD · Samel Hospital

  • Flavio Cadegiani, MD · Corpometria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2021-10-30
Completion
2021-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853927 on ClinicalTrials.gov